

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant:** Auerbach et al.

**Serial No.:** Not Yet Known

**Group:** Not Yet Assigned

**Filing Date:** Filed Herewith

**Examiner:** Not Yet Assigned

**Title:** Method of Improving Gene Targeting Using A Ubiquitin Promoter

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Respectfully submitted

  
\_\_\_\_\_  
Valeta Gregg

Reg. No. 35,127

Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

Att. Docket No. : REG 784  
Serial No. : to be assigned  
Applicant: : Auerbach, et al.  
Date Filed : Concurrently herewith  
For : METHOD OF IMPROVING GENE  
TARGETING USING A UBIQUITIN  
PROMOTER

Examiner : Not Yet Known  
Group Art Unit : Not Yet Known

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**U.S. PATENT DOCUMENTS**

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

**FOREIGN PATENT DOCUMENTS**

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	_____	_____	_____	_____	_____

OTHER DOCUMENTS

Examiner  
Initials

\_\_\_\_\_ NUCLEIC ACIDS RESEARCH, Vol. 24, 1996, Schorpp, M., et  
al. "The human ubiquitin C promoter directs high  
ubiquitous expression of transgenes in mice" pp. 1787-1788.

EXAMINER  
CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in  
conformance with MPEP 609; draw line through citation if  
not in conformance and not considered. Include copy of this  
form with next communication to applicant.

Respectfully submitted,

By:

Valeta Gregg  
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400